摘要: Angiogenesis, the formation of new blood vessels from existing vasculature, is a physiological process in wound healing and menstrual cycle, but has pathological role several diseases, such as retinopathy, rheumatoid arthritis cancer. One hallmarks cancer presence sustained angiogenesis after tumors have made angiogenic switch [1, 21]. Angiogenesis multi-step which endothelial cells to become activated, subsequently proliferate migrate direction stimulus, will only be possible breakdown remodeling extracellular matrix (ECM) so that tube can take place. Finally, newly formed vessel stabilized by pericytes fibroblasts. This complicated highly orchestrated regulated multiple factors, growth proteases (matrix metalloproteases) integrins. Important driving forces tumor-induced are hypoxia oncogenes [3, 4, 5, 6]. Hypoxia induces via inducible factor 1α (HIF-1α) expression whereas mutated and/or activated also capable inducing upregulation stimulating factors downregulation inhibiting genes proteins.
springer.com
sci-hub.st 参考文章(71)
Janusz Rak, Joanne L. Yu, Giannoula Klement, Robert S. Kerbel, Oncogenes and angiogenesis: signaling three-dimensional tumor growth. The journal of investigative dermatology. Symposium proceedings / the Society for Investigative Dermatology, Inc. [and] European Society for Dermatological Research. ,vol. 5, pp. 24- 33 ,(2000) , 10.1046/J.1087-0024.2000.00012.X
Z Zhu, K Hattori, H Zhang, X Jimenez, D L Ludwig, S Dias, P Kussie, H Koo, H J Kim, D Lu, M Liu, R Tejada, M Friedrich, P Bohlen, L Witte, S Rafii, Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity. Leukemia. ,vol. 17, pp. 604- 611 ,(2003) , 10.1038/SJ.LEU.2402831
Bart C Kuenen, Lee Rosen, Egbert F Smit, Mandy RN Parson, Marcel Levi, Rita Ruijter, Holger Huisman, Marc A Kedde, Paul Noordhuis, Wim JF Van Der Vijgh, Godefridus J Peters, Gillian F Cropp, Paul Scigalla, Klaus Hoekman, Herbert M Pinedo, Giuseppe Giaccone, Dose-Finding and Pharmacokinetic Study of Cisplatin, Gemcitabine, and SU5416 in Patients With Solid Tumors Journal of Clinical Oncology. ,vol. 20, pp. 1657- 1667 ,(2002) , 10.1200/JCO.20.6.1657
Darren W. Davis, Yu Shen, Nizar A. Mullani, Sijin Wen, Roy S. Herbst, Michael O’Reilly, James L. Abbruzzese, David J. McConkey, Quantitative Analysis of Biomarkers Defines an Optimal Biological Dose for Recombinant Human Endostatin in Primary Human Tumors Clinical Cancer Research. ,vol. 10, pp. 33- 42 ,(2004) , 10.1158/1078-0432.CCR-0736-3
David H Johnson, Louis Fehrenbacher, William F Novotny, Roy S Herbst, John J Nemunaitis, David M Jablons, Corey J Langer, Russell F DeVore III, Jacques Gaudreault, Lisa A Damico, Eric Holmgren, Fairooz Kabbinavar, Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer Journal of Clinical Oncology. ,vol. 22, pp. 2184- 2191 ,(2004) , 10.1200/JCO.2004.11.022
Nicole Meyer-Morse, Gabriele Bergers, Emily Bergsland, Steven Song, Douglas Hanahan, Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors Journal of Clinical Investigation. ,vol. 111, pp. 1287- 1295 ,(2003) , 10.1172/JCI17929
Qi Ling, Andrew T. Jacovina, Arunkumar Deora, Maria Febbraio, Ronit Simantov, Roy L. Silverstein, Barbara Hempstead, Willie H. Mark, Katherine A. Hajjar, Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo Journal of Clinical Investigation. ,vol. 113, pp. 38- 48 ,(2004) , 10.1172/JCI19684
Christopher G Willett, Yves Boucher, Emmanuelle di Tomaso, Dan G Duda, Lance L Munn, Ricky T Tong, Daniel C Chung, Dushyant V Sahani, Sanjeeva P Kalva, Sergey V Kozin, Mari Mino, Kenneth S Cohen, David T Scadden, Alan C Hartford, Alan J Fischman, Jeffrey W Clark, David P Ryan, Andrew X Zhu, Lawrence S Blaszkowsky, Helen X Chen, Paul C Shellito, Gregory Y Lauwers, Rakesh K Jain, Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer Nature Medicine. ,vol. 10, pp. 145- 147 ,(2004) , 10.1038/NM988
Carl-Henrik Heldin, Bengt Westermark, Mechanism of Action and In Vivo Role of Platelet-Derived Growth Factor Physiological Reviews. ,vol. 79, pp. 1283- 1316 ,(1999) , 10.1152/PHYSREV.1999.79.4.1283
Dirk B Mendel, Randall E Schreck, David C West, Guangmin Li, Laurie M Strawn, Sheila S Tanciongco, Stefan Vasile, Laura K Shawver, Julie M Cherrington, None, The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function. Clinical Cancer Research. ,vol. 6, pp. 4848- 4858 ,(2000)